三生制药CFO何翔增持300万股
财中社11月14日电三生制药（01530）发布公告，首席财务官何翔于2024年1月1日至公告日，通过集中竞价方式增持本公司股份共计300万股，平均增持价格约为5.99港元，增持股份占已发行股份总数的0.12%。何翔表示，认为股份长期处于低估状态，基于对公司业务及前景的信心，未来可能会继续增持股份。
进一步增持将视市场情况而定，并可能受到政策、市场变化及资金状况等因素的影响，存在延期或无法完成的风险。何翔在增持时确认未获知任何关于公司的内幕信息，增持行为为其自愿决定。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10